NCT05004116: A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: ALK, ROS, NTRK
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 1 Year to 25 Years (Child, Adult)
Location of Metastases: 
Additional Notes: Patients are not required to have tumors that express ALK, ROS, NTRK mutations
Exclusions: Patients over the age of 25; Patients with unstable or untreated central nervous system (brain or leptomeningeal) metastases that require steroids- see trial for details

Comments are closed.

Up ↑